West Point Pharmaceuticals Co., Ltd.

Announcement on the Implementation of Dividend Distribution for 2025

Legal Opinion on the 2025 Annual Shareholders Meeting of Jilin Xidian Pharmaceutical Technology Development Co., Ltd.

Announcement of Resolutions from the 2025 Annual Shareholders' Meeting

Announcement on the subsidiary's vitamin B6 injection obtaining a drug registration certificate

Announcement on Participation in the 2026 Online Collective Reception Day for Investors of Listed Companies in Jilin Province

Announcement on Shareholding Reduction by Shareholders Holding More than 5% and Their Concerted Actors Touching 1% Integer Multiple

Announcement on the Initial Grant of Restricted Stock to Incentive Objects under the 2026 Restricted Stock Incentive Plan

Verification Opinion from the Compensation and Assessment Committee of Jilin Xidian Pharmaceutical Technology Development Co., Ltd. on the Initial Grant of Restricted Stock Incentive Plan for 2026

Legal Opinion from Beijing Hairun Tianrui Law Firm on the Initial Grant of Restricted Stock Incentive Plan for Jilin Xidian Pharmaceutical Technology Development Co., Ltd. in 2026

Announcement of Resolutions from the 16th Meeting of the 8th Board of Directors

Guotai Junan Securities Co., Ltd. Special Verification Opinion on the Storage and Use of Funds Raised by Jilin Province Xidian Pharmaceutical Technology Development Co., Ltd. in 2025

Guotai Junan Securities Co., Ltd. Tracking Report on the 2025 Annual Continuous Supervision of Jilin Province Xidian Pharmaceutical Technology Development Co., Ltd.

Guotai Junan Securities Co., Ltd. Summary Report on the Sponsorship of the Initial Public Offering and Listing of Jilin Province Xidian Pharmaceutical Technology Development Co., Ltd.

Guotai Junan Securities Co., Ltd. Report on the On-Site Inspection of the 2025 Annual Continuous Supervision Work of Jilin Province Xidian Pharmaceutical Technology Development Co., Ltd.

Announcement on the Company's Proposal to Reappoint the Accounting Firm for 2026

2025 Annual Financial Settlement Report

2025 Annual Board Work Report

Announcement on the Confirmation of Compensation for Directors and Senior Management for the year 2025 and the Compensation Plan for the year 2026

2025 Annual Report of Independent Director (Su Bing)

2025 Annual Report of Independent Director (Lu Xiangjun)

2025 Annual Report of Independent Director (Wu Nannan)

2025 Annual Sustainable Development Report

Verification Opinion of Guotai Junan Securities Co., Ltd. on the Internal Control Evaluation Report of Jilin Province Xidian Pharmaceutical Technology Development Co., Ltd. for the year 2025

Internal Control Audit Report by Rongcheng Accounting Firm

Internal Control Evaluation Report for the year 2025

Announcement on Changes in Accounting Policies

Notice of the 2025 Annual Shareholders' Meeting

Resolution Announcement of the 16th Meeting of the 8th Board of Directors

Announcement on the Profit Distribution Plan for the year 2025

Q1 Report for 2026

Special Report on the Deposit, Management, and Use of Raised Funds for the year 2025

Verification Report on the Deposit and Use of Raised Funds for the year 2025 by Rongcheng Accounting Firm

Evaluation Report on the Performance of the Accounting Firm for the year 2025

Report on the Evaluation of the Performance of the Annual Audit Accounting Firm by the Audit Committee of the Board of Directors for the year 2025

Special Explanation of Non-Operating Fund Occupation and Other Related Fund Transactions by Rongcheng Accounting Firm

Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions for the year 2025

Special Opinion on the Independence of Independent Directors for the year 2025

2025 Annual Audit Report

2025 Annual Report

Summary of the 2025 Annual Report

Announcement on Participation in National Organized Procurement of Drugs at the End of Agreement Period

Beijing Hairun Tianrui Law Firm's Legal Opinion on the 2026 First Extraordinary Shareholders' Meeting of Jilin Xidian Pharmaceutical Technology Development Co., Ltd.

2026 First Extraordinary Shareholders' Meeting Resolution Announcement

Self-Inspection Report on the Stock Trading Situation of Insiders and Incentive Objects of the 2026 Restricted Stock Incentive Plan

Public disclosure and verification opinions of the list of incentive objects for the 2026 restricted stock incentive plan by the Board of Directors' Compensation and Assessment Committee

Announcement on the Company's Ferric Maltol Receiving Approval Notice for Marketing Application of Chemical Raw Material Drug

Pre-disclosure Announcement of Share Reduction by Shareholders Holding Over 5% of Shares and Their Concerted Parties

Announcement on the Company's Ferric Maltol Oral Solution Obtaining a Drug Registration Certificate

Announcement on Changing the Names of Special Committees of the Board of Directors and Revising Their Implementation Rules

Implementation Rules for the Board of Directors' Strategy and Sustainable Development Committee

Equity Incentive Management System

Emergency Response System for Contingencies

Articles of Association of Jilin Xidian Pharmaceutical Technology Development Co., Ltd.

Remuneration Management System for Directors and Senior Management

Announcement on Revising the Articles of Association and Revising and Formulating Certain Company Systems

Notice of Convening the First Interim Shareholders' Meeting in 2026

Announcement of Resolutions of the 15th Meeting of the Eighth Board of Directors

Beijing Hairun Tianrui Law Firm's Legal Opinion on Jilin Xidian Pharmaceutical Technology Development Co., Ltd.'s 2026 Restricted Stock Incentive Plan (Draft)

Jilin Xidian Pharmaceutical Technology Development Co., Ltd. Remuneration and Assessment Committee's Verification Opinion on Matters Related to the 2026 Restricted Stock Incentive Plan

Jilin Xidian Pharmaceutical Technology Development Co., Ltd. 2026 Restricted Stock Incentive Plan Self-Inspection Form

Jilin Xidian Pharmaceutical Technology Development Co., Ltd. 2026 Restricted Stock Incentive Plan Implementation Assessment Management Measures

Jilin Xidian Pharmaceutical Technology Development Co., Ltd. 2026 Restricted Stock Incentive Plan (Draft)

Jilin Xidian Pharmaceutical Technology Development Co., Ltd. 2026 Restricted Stock Incentive Plan (Draft) Summary

Announcement on Share Repurchase Results and Share Changes

Progress Announcement Regarding Share Repurchase Ratio Reaching 1%

"Announcement on the change of continuous supervision sponsor representatives",